2012 financial results: a window on the future
Posted by
27-Feb-2013
They say a picture paints a thousand words. Sometimes I feel the same way about numbers – they tell their own story.
Read UCB’s financial results for 2012 and, behind the revenue figure of €3 462 billion, take a look at where the sales growth is coming from.
Combined net sales for our three new core medicines reached €934 million – an increase of 49% on 2011. These products, which are used to treat rheumatoid arthritis, Crohn’s disease, epilepsy, Parkinson’s disease, and restless legs syndrome have eclipsed sales of UCB’s established epilepsy drug.
The figures tell you something about the future. As I explained last October, this ‘cross over’ is the inflection point which marks UCB’s transformation into a patient-centric biopharmaceutical company.
In the years ahead, the company is looking to these three ‘younger’ core products as a key driver of company growth. Their strong performance is expected to continue, thanks in part to broadening patient access, recent launches in new markets and the potential for new indications based on recent filings and on-going clinical trials.
Of course, our drive has always come from taking a long-term view of the future. That is why we continue to invest in promising new medicines. At the same time, we managed to deliver on our financial outlook: underlying profitability (recurring EBITDA) reached €655 million.
Going forward, UCB's 5 strategic growth priorities are:
. Grow core medicines
. Build emerging markets and Japan
. Advance the rich late-stage pipeline
. Deliver breakthrough medicines to the clinic
. Reach competitive profitability.
We aspire to be one of the leaders bringing solutions to people suffering from severe diseases: I am convinced that maximizing sustainable and superior value for patients means to maximize shareholder value.
For more information, please contact Antje Witte.
Read UCB’s financial results for 2012 and, behind the revenue figure of €3 462 billion, take a look at where the sales growth is coming from.
Combined net sales for our three new core medicines reached €934 million – an increase of 49% on 2011. These products, which are used to treat rheumatoid arthritis, Crohn’s disease, epilepsy, Parkinson’s disease, and restless legs syndrome have eclipsed sales of UCB’s established epilepsy drug.
The figures tell you something about the future. As I explained last October, this ‘cross over’ is the inflection point which marks UCB’s transformation into a patient-centric biopharmaceutical company.
In the years ahead, the company is looking to these three ‘younger’ core products as a key driver of company growth. Their strong performance is expected to continue, thanks in part to broadening patient access, recent launches in new markets and the potential for new indications based on recent filings and on-going clinical trials.
Of course, our drive has always come from taking a long-term view of the future. That is why we continue to invest in promising new medicines. At the same time, we managed to deliver on our financial outlook: underlying profitability (recurring EBITDA) reached €655 million.
Going forward, UCB's 5 strategic growth priorities are:
. Grow core medicines
. Build emerging markets and Japan
. Advance the rich late-stage pipeline
. Deliver breakthrough medicines to the clinic
. Reach competitive profitability.
We aspire to be one of the leaders bringing solutions to people suffering from severe diseases: I am convinced that maximizing sustainable and superior value for patients means to maximize shareholder value.
For more information, please contact Antje Witte.
Leave a Comment